Lupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 55707.38 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 31-03-2021, the company reported a Consolidated Total Income of Rs 3841.32 Crore, down -4.88 % from last quarter Total Income of Rs 4038.53 Crore and down -5.25 % from last year same quarter Total Income of Rs 4054.34 Crore. Company reported net profit after tax of Rs 464.20 Crore in latest quarter.
Investment Rationale
Limited competitive products (including g-Brovana) within the Respiratory segment, ramp-up of market share in existing products, supported by a recovery in the Domestic Formulation segment, provides scope for 35% earnings CAGR over FY21-23E. The brokerage values LPC at 25x 12-month forward earnings to arrive at TP of INR1,320. It maintains Neutral rating as the potential upside in earnings is adequately factored at current valuations.
Promoter/FII Holdings
Promoters held 46.9 per cent stake in the company as of March 31, 2021, while FIIs held 17.9 per cent, DIIs 22.6 per cent and public and others 12.7 per cent.
(Views and recommendations given in this section are the analysts’ own and do not represent those of ETMarkets.com. Please consult your financial adviser before taking any position in the stock/s mentioned.)
